News

News

Pre-clinical (in-vivo & in-vitro) Study Report from Holy Stone Healthcare's CA102N

17, Apr 2017
A pre-clinical (in-vivo & in-vitro) study report from Holy Stone Healthcare's novel targeting anti-cancer drug in colorectal cancer, CA102N, is published on《Nanomedicine》, volume 2017:12 on March 27, 2017.

For more information, please visit https://www.dovepress.com/hyaluronic-acidndashnimesulide-conjugates-as-anticancer-drugs-against--peer-reviewed-fulltext-article-IJN#
 
previous page